@article{article_549939, title={PROPHYLAXIS FOR HEMOPHILIA A PATIENTS WITH INHIBITORS}, journal={Türkiye Çocuk Hastalıkları Dergisi}, volume={6}, pages={245–248}, year={2012}, author={Çulha, Vildan and Gökçebay, Dilek and Bilir, Özlem A. and Azık, M.fatih and Tavil, Betül and Işık, Pamir and Yaralı, Neşe and Kara, Abdurrahman and Tunç, Bahattin}, keywords={Hemophilia A, inhibitory, prophylaxis}, abstract={Use of activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa (rFVIIa) is indicated for the treatment and prophylaxis of hemophiliac patients who has developed inhibitors. rFVIIa is an off labeled drug for prophylaxis in Turkey and not covered by health insurance. In this manuscript, the efficacy and dosage for aPCC prophylaxis were evaluated. During the aPCC prophylaxis, bleeding did not occur in any of the three cases. However, two patients developed recurrent bleeding attacks after the prophylaxis ceased. Therefore, we suggest that prophylaxis by aPCC should be prolonged to prevent recurrent bleeding attacks in hemophiliacs who developed inhibitors}, number={4}, publisher={T.C. Sağlık Bakanlığı Ankara Şehir Hastanesi}